BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a high risk of induction failure and poor outcomes, with relapse due to drug resistance. Recent studies show that bromodomains and extra-terminal (BET) protein inhibitors are promising anti-cancer agents. ARV-825,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shuiyan, Jiang, You, Hong, Yi, Chu, Xinran, Zhang, Zimu, Tao, Yanfang, Fan, Ziwei, Bai, Zhenjiang, Li, Xiaolu, Chen, Yanling, Li, Zhiheng, Ding, Xin, Lv, Haitao, Du, Xiaoli, Lim, Su Lin, Zhang, Yongping, Huang, Saihu, Lu, Jun, Pan, Jian, Hu, Shaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061034/
https://www.ncbi.nlm.nih.gov/pubmed/33888130
http://dx.doi.org/10.1186/s12935-021-01908-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061034/
https://www.ncbi.nlm.nih.gov/pubmed/33888130
http://dx.doi.org/10.1186/s12935-021-01908-w

Ejemplares similares